BUSINESS WIRE: Ipsens first quarter 2014 sales

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

PARIS --(BUSINESS WIRE)-- 30.04.2014 --

RegulatoryNews:

Ipsen (Euronext: IPN; ADR: IPSEY) reported today its sales for the first quarter 2014.

First quarter 2014 unaudited IFRS consolidated sales

Drug-related sales2

Commenting on the first quarter 2014 performance, Marc de Garidel, Chairman and Chief Executive Officer of Ipsen said: Ipsen is off to a good start this year with solid specialty care growth, up 6.4%1, notably driven by the good performance of Somatulineand Dysportand the return to growth of Decapeptylin China. Moreover, Primary Care, negatively impacted by a continuous decline in France, benefited from strong international growth. Marc de Garidel added: The Group is paying special attention to the potential consolidations that may alter the competitive landscape in its areas of interest.

1 Year-on-year growth excluding foreign exchange impacts 2 Drug related sales correspond to sales of active indredients and raw materials

First quarter 2014 sales highlights

Note: Unless stated otherwise, all variations in sales are stated excluding foreign exchange impacts by restating the Q1 2013 sales with the Q1 2014 exchange rates.

Read the original:
BUSINESS WIRE: Ipsens first quarter 2014 sales